Page last updated: 2024-08-24

propazole and Diabetes Mellitus, Type 2

propazole has been researched along with Diabetes Mellitus, Type 2 in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Cashion, D; Chapman, KT; Chen, Y; Dang, Q; Gibson, T; He, H; Kassick, AJ; Lan, P; Li, Y; MacKenna, D; Makara, GM; Romero, FA; Sebhat, IK; Shao, Q; Staunton, J; Trujillo, ME; Weber, A; Wodka, D; Wu, M; Xu, S; Zhang, A; Zhang, X; Zhou, G	1

Other Studies

1 other study(ies) available for propazole and Diabetes Mellitus, Type 2

Article	Year
Hit-to-Lead Optimization and Discovery of 5-((5-([1,1'-Biphenyl]-4-yl)-6-chloro-1H-benzo[d]imidazol-2-yl)oxy)-2-methylbenzoic Acid (MK-3903): A Novel Class of Benzimidazole-Based Activators of AMP-Activated Protein Kinase. Journal of medicinal chemistry, 2017, 11-09, Volume: 60, Issue:21 Topics: Administration, Oral; AMP-Activated Protein Kinases; Animals; Benzimidazoles; Diabetes Mellitus, Type 2; Drug Discovery; Insulin Resistance; Lipid Metabolism; Mice	2017

Article

Year

Hit-to-Lead Optimization and Discovery of 5-((5-([1,1'-Biphenyl]-4-yl)-6-chloro-1H-benzo[d]imidazol-2-yl)oxy)-2-methylbenzoic Acid (MK-3903): A Novel Class of Benzimidazole-Based Activators of AMP-Activated Protein Kinase.

Journal of medicinal chemistry, 2017, 11-09, Volume: 60, Issue:21

Topics: Administration, Oral; AMP-Activated Protein Kinases; Animals; Benzimidazoles; Diabetes Mellitus, Type 2; Drug Discovery; Insulin Resistance; Lipid Metabolism; Mice

2017